Key Points
- Insider sale: Fernando Rodrigues sold 4,209 shares on Dec. 3 at an average price of $7.48 for total proceeds of $31,483.32, disclosed in an SEC Form 4.
- Q3 results & guidance: Teladoc posted EPS of -$0.21 (beat -$0.26) and revenue of $626.44M (down 2.2% YoY), and set Q4 2025 guidance of -0.25 to -0.10 EPS while analysts expect -1.16 EPS for the fiscal year.
- Market and analyst context: Shares trade near $7.39 (12‑month range $6.35–$15.21) with a $1.31B market cap, ~76.8% institutional ownership, and an average analyst rating of Hold with a $9.68 target.
Teladoc Health, Inc. (NYSE:TDOC - Get Free Report) insider Fernando Rodrigues sold 2,324 shares of the company's stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $7.49, for a total transaction of $17,406.76. Following the completion of the sale, the insider owned 4,209 shares of the company's stock, valued at approximately $31,525.41. This trade represents a 35.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Teladoc Health Stock Performance
Teladoc Health stock traded down $0.16 during midday trading on Thursday, hitting $7.38. 326,776 shares of the company's stock were exchanged, compared to its average volume of 7,012,550. The firm's 50 day simple moving average is $8.02 and its 200 day simple moving average is $7.76. Teladoc Health, Inc. has a 12-month low of $6.35 and a 12-month high of $15.21. The company has a debt-to-equity ratio of 0.71, a quick ratio of 2.60 and a current ratio of 2.70. The stock has a market cap of $1.31 billion, a price-to-earnings ratio of -5.76 and a beta of 2.04.
Teladoc Health (NYSE:TDOC - Get Free Report) last issued its quarterly earnings results on Wednesday, October 29th. The health services provider reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.05. Teladoc Health had a negative return on equity of 10.59% and a negative net margin of 8.84%.The firm had revenue of $626.44 million for the quarter, compared to analysts' expectations of $625.66 million. During the same quarter in the previous year, the firm posted ($0.19) EPS. The firm's revenue for the quarter was down 2.2% on a year-over-year basis. Teladoc Health has set its Q4 2025 guidance at -0.250--0.100 EPS. Equities research analysts predict that Teladoc Health, Inc. will post -1.16 EPS for the current year.
Institutional Trading of Teladoc Health
Several large investors have recently bought and sold shares of TDOC. National Bank of Canada FI increased its position in shares of Teladoc Health by 79.4% in the first quarter. National Bank of Canada FI now owns 3,571 shares of the health services provider's stock valued at $28,000 after buying an additional 1,581 shares in the last quarter. IFP Advisors Inc increased its holdings in Teladoc Health by 412.1% during the 3rd quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider's stock valued at $31,000 after acquiring an additional 3,210 shares in the last quarter. SVB Wealth LLC purchased a new stake in shares of Teladoc Health in the first quarter valued at about $37,000. Aster Capital Management DIFC Ltd grew its position in shares of Teladoc Health by 101.1% in the third quarter. Aster Capital Management DIFC Ltd now owns 4,823 shares of the health services provider's stock valued at $37,000 after purchasing an additional 2,425 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Teladoc Health during the 1st quarter worth approximately $50,000. Institutional investors and hedge funds own 76.82% of the company's stock.
Analysts Set New Price Targets
TDOC has been the topic of several recent research reports. BMO Capital Markets began coverage on shares of Teladoc Health in a research note on Thursday, November 13th. They issued a "market perform" rating and a $8.00 price objective on the stock. Evercore ISI dropped their target price on Teladoc Health from $9.00 to $8.00 and set an "in-line" rating on the stock in a research report on Thursday, October 30th. Citigroup raised their price target on Teladoc Health from $9.50 to $10.50 and gave the company a "neutral" rating in a report on Tuesday, October 21st. Zacks Research lowered Teladoc Health from a "strong-buy" rating to a "hold" rating in a report on Monday, November 10th. Finally, Bank of America reduced their target price on Teladoc Health from $9.00 to $8.00 and set a "neutral" rating for the company in a report on Tuesday, November 25th. Five equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Teladoc Health currently has an average rating of "Hold" and an average target price of $9.68.
Read Our Latest Stock Report on Teladoc Health
Teladoc Health Company Profile
(
Get Free Report)
Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
